MetaCap

Alzamend Neuro (ALZN) vs NuCana (NCNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alzamend Neuro is the larger company by market cap ($3.7 million vs $3.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALZN-43.37%NCNA-34.25%
+16%-15%-46%
Oct 7, 20261 yearNov 20, 2026
ALZN-42.10%NCNA-31.86%
+8%-18%-44%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALZN versus NCNA key metrics
MetricALZNNCNA
Share price$0.7758$0.7495
Market cap$3.74M$3.61M
1-day change-23.94%+4.39%
EPS (TTM)$-2.30$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M—
52-week high$2.54$4.55
52-week low$0.754$0.62
Distance from 52-week high-69.40%-83.53%
Analyst consensusnone—
Avg. price target upside+3251.38%—
Average volume70.27K118.13K
Shares outstanding4.83M4.82M
Employees410
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alzamend Neuro

ALZN stock →

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About NuCana

NCNA stock →

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ALZN vs NCNA FAQ

Which is bigger, Alzamend Neuro or NuCana?

Alzamend Neuro (ALZN) is larger, with a market capitalization of $3.74M compared with $3.61M for NuCana (NCNA).

Are Alzamend Neuro and NuCana in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons